-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
【Chemical Machinery and Equipment Network Industry News】Capital operation refers to the company's use of asset restructuring, enterprise mergers and acquisitions, venture capital and financing and other means to improve the capital structure and maximize capital multiplication
.
Capital operation is a powerful booster, which can realize the reasonable flow of capital, the adjustment of industrial structure, and the overall improvement of macro industry at the macro level, and can improve the competitiveness and operating efficiency of enterprises at the micro level, rapidly expand the scale of enterprises, and have a huge role
in promoting the development of enterprises.
.
Capital operation is a powerful booster, which can realize the reasonable flow of capital, the adjustment of industrial structure, and the overall improvement of macro industry at the macro level, and can improve the competitiveness and operating efficiency of enterprises at the micro level, rapidly expand the scale of enterprises, and have a huge role
in promoting the development of enterprises.
Recently, the editor of Chemical Instrument Network sorted out the capital dynamics of the instrument circle in November 2022, and the main contents of the instrument capital dynamics in November include: the new opening of the North China Customer Application and Innovation Center of Sartorius; Situofan announced an increase of 60 million yuan to build a China science and technology innovation center; Merck announces partnership with Promethes; Bruker announces acquisition of Inscopix; Danaher announces strategic partnership with Duke University; Shimadzu announces Nissizu Pharmaceutical as its wholly owned subsidiary.
.
.
.
.
Sartorius North China Customer Application and Innovation Center was newly opened
On November 1, Sartorius announced the official opening of the North China Customer Application and Innovation Center
.
Located in Yantai, Shandong Province, the center will simplify and accelerate the development of
life sciences and bioprocesses.
The center is another important milestone
in Sartorius' localization strategy.
It is understood that next year Sartorius will open more application and innovation centers
in other cities such as Chengdu.
.
Located in Yantai, Shandong Province, the center will simplify and accelerate the development of
life sciences and bioprocesses.
The center is another important milestone
in Sartorius' localization strategy.
It is understood that next year Sartorius will open more application and innovation centers
in other cities such as Chengdu.
Situofan announced an increase of 60 million yuan to build a science and technology innovation center in China
On November 5, Situofan announced that it will increase its capital by 60 million yuan in China to build a Chinese science and technology innovation center, and release localized new products to accelerate the innovation and high-quality development
of the local biopharmaceutical industry.
It is understood that Situofan China Science and Technology Innovation Center is located in Zhangjiang, Shanghai, and will aggregate 7 functional divisions
: biopharmaceutical talent training base, new therapy incubator, digital remote service center, one-time technology research and development excellence center, biointelligent manufacturing display platform, customized bioprocessing solution center, and regulatory verification laboratory.
of the local biopharmaceutical industry.
It is understood that Situofan China Science and Technology Innovation Center is located in Zhangjiang, Shanghai, and will aggregate 7 functional divisions
: biopharmaceutical talent training base, new therapy incubator, digital remote service center, one-time technology research and development excellence center, biointelligent manufacturing display platform, customized bioprocessing solution center, and regulatory verification laboratory.
Merck announces partnership with Pumis
On November 7, Merck announced a partnership
with Purmeis Biotechnology (Zhuhai) Co.
, Ltd.
("Purmes").
Merck's Blazar® testing platform can help Purmeis accelerate the passage of new drug clinical research approval (IND) and biologics marketing application (BLA)
in China and other countries and regions.
with Purmeis Biotechnology (Zhuhai) Co.
, Ltd.
("Purmes").
Merck's Blazar® testing platform can help Purmeis accelerate the passage of new drug clinical research approval (IND) and biologics marketing application (BLA)
in China and other countries and regions.
Bruker announces the acquisition of Inscopix
On November 8, Bruker announced the acquisition of Inscopix, a company that develops miniature microscopes that can be used to image
the brains of free-moving animals.
The acquisition combines Bruker's multiphoton microscope with Inscopix's free-moving head-mounted imaging to help Bruker explore the capabilities of animal neural networks and develop new and better neurotherapies
.
the brains of free-moving animals.
The acquisition combines Bruker's multiphoton microscope with Inscopix's free-moving head-mounted imaging to help Bruker explore the capabilities of animal neural networks and develop new and better neurotherapies
.
Danaher announces a strategic partnership with Duke University
On November 10, Danaher announced a strategic partnership with Duke University to establish the first Danaher Beacon initiative to drive gene therapy innovation
.
The Danaher Lighthouse is a new initiative to gain groundbreaking scientific results to develop technologies and applications
that improve human health.
The project will focus investments in product innovation to advance external R&D strategies with a focus on genomic medicine, precision diagnostics, next-generation biomanufacturing, human systems, and data science
.
.
The Danaher Lighthouse is a new initiative to gain groundbreaking scientific results to develop technologies and applications
that improve human health.
The project will focus investments in product innovation to advance external R&D strategies with a focus on genomic medicine, precision diagnostics, next-generation biomanufacturing, human systems, and data science
.
Shimadzu announces that Nissui Pharmaceutical has become its wholly owned subsidiary
On November 15, Shimadzu took advantage of the share merger privilege to develop Nissui Pharmaceutical into a wholly-owned subsidiary
.
Nissei Pharmaceutical's extensive clinical sales channels, abundant reagent-related technologies and expertise, combined with Shimadzu's analytical and measuring instrument division, will create synergies in the three business areas of clinical diagnostics, microbial testing, and cell analysis, and help Shimadzu expand its healthcare business
.
.
Nissei Pharmaceutical's extensive clinical sales channels, abundant reagent-related technologies and expertise, combined with Shimadzu's analytical and measuring instrument division, will create synergies in the three business areas of clinical diagnostics, microbial testing, and cell analysis, and help Shimadzu expand its healthcare business
.
Original: Instrument FocusNovember 2022 Instrument Circle Capital Dynamics (Part I)
